Nishio K - Search Results

1

aCGH Analysis of Predictive Biomarkers for Response to Bevacizumab plus Oxaliplatin- or Irinotecan-Based Chemotherapy in Patients with Metastatic Colorectal Cancer.

Fujita Y, Taguri M, Yamazaki K, Tsurutani J, Sakai K, Tsushima T, Nagase M, Tamagawa H, Ueda S, Tamura T, Tsuji Y, Murata K, Taira K, Denda T, Moriwaki T, Funai S, Nakajima TE, Muro K, Tsuji A, Yoshida M, Suyama K, Kurimoto T, Sugimoto N, Baba E, Seki N, Sato M, Shimura T, Boku N, Hyodo I, Yamanaka T, Nishio K. Fujita Y, et al. Among authors: nishio k. Oncologist. 2019 Mar;24(3):327-337. doi: 10.1634/theoncologist.2018-0119. Epub 2018 Nov 13. Oncologist. 2019. PMID: 30425180 Free PMC article. Clinical Trial.

2

Determinants of response to the DNA topoisomerase II inhibitors doxorubicin and etoposide in human lung cancer cell lines.

Kasahara K, Fujiwara Y, Sugimoto Y, Nishio K, Tamura T, Matsuda T, Saijo N. Kasahara K, et al. Among authors: nishio k. J Natl Cancer Inst. 1992 Jan 15;84(2):113-8. doi: 10.1093/jnci/84.2.113. J Natl Cancer Inst. 1992. PMID: 1310509

3

7-Ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxy camptothecin: mechanism of resistance and clinical trials.

Saijo N, Nishio K, Kubota N, Kanzawa F, Shinkai T, Karato A, Sasaki Y, Eguchi K, Tamura T, Ohe Y, et al. Saijo N, et al. Among authors: nishio k. Cancer Chemother Pharmacol. 1994;34 Suppl:S112-7. doi: 10.1007/BF00684874. Cancer Chemother Pharmacol. 1994. PMID: 8070019 Review.

4

Apoptosis induced by etoposide in small-cell lung cancer cell lines.

Okamoto-Kubo S, Nishio K, Heike Y, Yoshida M, Ohmori T, Saijo N. Okamoto-Kubo S, et al. Among authors: nishio k. Cancer Chemother Pharmacol. 1994;33(5):385-90. doi: 10.1007/BF00686267. Cancer Chemother Pharmacol. 1994. PMID: 8306412

5

Overcoming drug resistance in lung cancer.

Saijo N, Nishio K, Yoshida M. Saijo N, et al. Among authors: nishio k. Oncology (Williston Park). 1998 Jan;12(1 Suppl 2):87-9. Oncology (Williston Park). 1998. PMID: 9516619 Free article. Review.

6

Problems in the development of target-based drugs.

Saijo N, Tamura T, Nishio K. Saijo N, et al. Among authors: nishio k. Cancer Chemother Pharmacol. 2000;46 Suppl:S43-5. doi: 10.1007/pl00014049. Cancer Chemother Pharmacol. 2000. PMID: 10950147 Review.

7

Oncoprotein 18 overexpression increases the sensitivity to vindesine in the human lung carcinoma cells.

Nishio K, Nakamura T, Koh Y, Kanzawa F, Tamura T, Saijo N. Nishio K, et al. Cancer. 2001 Apr 15;91(8):1494-9. doi: 10.1002/1097-0142(20010415)91:8<1494::aid-cncr1157>3.0.co;2-7. Cancer. 2001. PMID: 11301397

8

CPT-11 alters the circadian rhythm of dihydropyrimidine dehydrogenase mRNA in mouse liver.

Shimizu M, Tamura T, Yamada Y, Akiyama Y, Saijo N, Nishio K. Shimizu M, et al. Among authors: nishio k. Jpn J Cancer Res. 2001 May;92(5):554-61. doi: 10.1111/j.1349-7006.2001.tb01129.x. Jpn J Cancer Res. 2001. PMID: 11376565 Free PMC article.

9

New strategies for cancer therapy in the 21st century.

Saito N, Tamura T, Yamamoto N, Nishio K. Saito N, et al. Among authors: nishio k. Cancer Chemother Pharmacol. 2001 Aug;48 Suppl 1:S102-6. doi: 10.1007/s002800100315. Cancer Chemother Pharmacol. 2001. PMID: 11587358 Review.

10

Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor.

Kimura H, Sakai K, Arao T, Shimoyama T, Tamura T, Nishio K. Kimura H, et al. Among authors: nishio k. Cancer Sci. 2007 Aug;98(8):1275-80. doi: 10.1111/j.1349-7006.2007.00510.x. Epub 2007 May 13. Cancer Sci. 2007. PMID: 17498200 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,216 results

Search Page

Filters